SCHEMBL4014944

SCHEMBL4014944

CCCCC(C)CC(CNC(=O)[C@@H](N)C(C)CC)CC(=O)O

nearest known ligand 0.38

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
GPR88 Q9GZN0 4/20 0.38
TERT O14746 1/20 0.35
DPP7 Q9UHL4 4/20 0.35
SLC15A1 P46059 1/20 0.35
DPP8 Q6V1X1 3/20 0.34
DPP4 P27487 2/20 0.34
DPP9 Q86TI2 2/20 0.34
ENPEP Q07075 5/20 0.34
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
SLC1A3 P43003 1/20 0.33
SLC1A2 P43004 1/20 0.33
SLC1A1 P43005 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4010429 1.00 GPR88 (0.38) GPR88TERTDPP7SLC15A1DPP8
SCHEMBL4007908 1.00 GPR88 (0.38) GPR88TERTDPP7SLC15A1DPP8
SCHEMBL4008680 0.92 GPR88 (0.43) GPR88TERTENPEP
SCHEMBL4009945 0.92 GPR88 (0.43) GPR88TERTENPEP
SCHEMBL4014849 0.92 GPR88 (0.43) GPR88TERTENPEP
SCHEMBL4009524 0.90 DPP7 (0.44) GPR88DPP7SLC15A1DPP8DPP4
SCHEMBL4008978 0.90 DPP7 (0.44) GPR88DPP7SLC15A1DPP8DPP4
SCHEMBL4008015 0.90 DPP7 (0.44) GPR88DPP7SLC15A1DPP8DPP4
SCHEMBL4014255 0.88 TERT (0.38) GPR88TERTDPP8DPP4DPP9
SCHEMBL4010231 0.88 TERT (0.38) GPR88TERTDPP8DPP4DPP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7491835-B2 Prodrugs of amino acids with affinity for the α2δ-protein PFIZER INC (US) 2009-02-17 US claimed
US-20050070483-A1 Prodrugs of amino acids with affinity for the alpha2delta-protein VIATRIS SPECIALTY LLC. 2005-03-31 US claimed
US-7491835-B2 Prodrugs of amino acids with affinity for the α2δ-protein PFIZER INC (US) 2009-02-17 US disclosed
EP-1670750-A1 PRODRUGS OF AMINO ACIDS WITH AFFINITY FOR THE ALPHA2DELTA- PROTEIN Warner-Lambert Company LLC (US) 2006-06-21 EP disclosed
WO-2005030703-A1 PRODRUGS OF AMINO ACIDS WITH AFFINITY FOR THE α2δ- PROTEIN WARNER-LAMBERT COMPANY LLC (US) 2005-04-07 WO disclosed
US-20050070483-A1 Prodrugs of amino acids with affinity for the alpha2delta-protein VIATRIS SPECIALTY LLC. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070483-A1 Prodrugs of amino acids with affinity for the alpha2delta-protein SCN2A, OPRD1, SCN1A GPR88 767/4885TERT 4876/4885DPP7 1105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.